Why did the CSL share price drop about 5% today?

Investors reacted to the CSL CEO resignation of Paul McKenzie, announced late on 10 February. The board said the timing, a day before results, was to keep focus on performance and outlook. Leadership changes often raise near‑term uncertainty, which can compress valuation and pressure the share price temporarily.

Is CSL a buy after the leadership change?

On balance, valuation is around a 20.5 PE with a 2.51% dividend yield. Meyka’s Stock Grade is B+ with a BUY suggestion, while our Company Rating is B+ but Neutral. That split reflects solid fundamentals but near‑term uncertainty. Position sizing and a plan around A$175 support can help manage risk.

What key levels should traders watch on CSL ASX?

Immediate resistance is A$182 to A$183, then the 200‑day average near A$212.75. First support is the 50‑day around A$177.14, then A$175 and the 52‑week low at A$168.00. A close above A$183 or below A$175 may signal momentum. Use stops, as volatility can rise around results.

When are CSL results and what matters most?

Results are due on 10 February. Watch guidance on revenue growth, Seqirus margins, and plasma collection costs. Debt metrics and cash generation will inform dividend capacity. Any update on the interim leadership plan and timeline for a new CEO could be a key driver for confidence and valuation.

Global Market Insights

CSL.AX Stock Today: CEO Exit Triggers 5% Selloff — February 10

ByHuzaifa Zahoor February 10, 2026February 10, 2026

The CSL share price came under pressure after the board ousted CEO Paul McKenzie and appointed an interim leader on 10 February, a day before results. The late announcement sparked a sharp intraday slide of about 5% as sellers hit healthcare names. The CSL.AX last traded near A$180.37. For Australian investors, the key now is guidance, capital allocation, and how quickly stability returns. We break down the market reaction, today’s price levels, and what the CSL ASX community should monitor into earnings.